9
Participants
Start Date
February 24, 2021
Primary Completion Date
September 24, 2021
Study Completion Date
September 24, 2021
Bosutinib 400 MG Monotherapy
One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario La Paz, Madrid
Collaborators (1)
Pfizer
INDUSTRY
Roche Farma, S.A
INDUSTRY
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
OTHER